CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, announced today that it has signed a merger agreement with ReShape Lifesciences (NASDAQ:RSLS). Upon closing, it is anticipated that the post-merger entity, will be renamed Vyome Holdings, Inc., and continue to have its common stock traded on Nasdaq under the new ticker symbol "HIND", an ancient na ...

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat ImmunoInflammatory Diseases of Unmet Need, to Combine in All-Stock Merger ReShape to Sell its Assets to Affiliate of Biorad Medisys for $5.16 Million Simultaneously with the execution of the merger agreement, ReShape entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., which is party to a previously disclosed exclusive license agreement with ReShape for ReShape's Obalon® Gastric Balloon System. Pursuant ...

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat ImmunoInflammatory Diseases of Unmet Need, to Combine in All-Stock Merger Under the terms of the merger agreement, which has been unanimously approved by the boards of directors of both companies, existing ReShape stockholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's actual net cash at closing compared to a target net cash ...

Exhibit 99.1 ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update Revenue totaled $1.9 million for the three months ended March 31, 2024, which represents a contraction of 15.0%, or $0.3 million compared to the same period in 2023. The primary reason is due to a decrease in sales volume primarily due to GLP-1 pharmaceuticals. Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% ...

财务数据和关键指标变化 - 公司2024年第一季度收入为1.9亿美元,较2023年同期下降15%或0.3亿美元,主要原因是销量下降,主要受到GLP-1药物的影响 [38] - 毛利润在2024年第一季度和2023年第一季度均为1.2亿美元,毛利率从2023年第一季度的54%提高到2024年第一季度的60%,主要由于公司在2023年末裁员导致相关成本下降 [40] - 销售和营销费用从2023年第一季度的2.2亿美元下降53%至1亿美元,主要是广告和营销费用下降0.7亿美元,以及薪酬相关费用下降0.5亿美元 [41] - 一般管理费用从2023年第一季度的4.2亿美元下降56%至1.9亿美元,主要是专业服务费用下降1.3亿美元,以及薪酬相关费用下降0.5亿美元 [42] - 研发费用在2024年第一季度为0.5亿美元,与2023年第一季度基本持平 [43] - 非GAAP调整后EBITDA亏损从2023年第一季度的5.3亿美元减少至2.1亿美元,主要由于持续降低整体运营成本 [44] - 公司在2024年第一季度末的净营运资本约为4.4亿美元,主要由于现金和现金等价物2.5亿美元以及应收账款1.6亿美元,且公司资产负债表上无债务 [45] 各条业务线数据和关键指标变化 - 公司的主要业务是Lap-Band手术,其中Lap-Band 2.0 FLEX新产品在2月份开始有首批手术,并获得了积极的外科医生反馈,预计将成为公司Lap-Band业务的增长动力 [25][26][29] - 公司正在努力获得Lap-Band 2.0 FLEX在加拿大和欧盟的监管批准,以拓展国际市场 [25] - 公司还通过培训外科医生和外科实习生来推广Lap-Band手术,为未来的Lap-Band业务发展奠定基础 [27] 各个市场数据和关键指标变化 - 公司目前仅在美国市场销售Lap-Band产品,正在努力拓展加拿大和欧盟市场 [25] - 公司通过与Hive Medical的合作,利用数字营销和患者参与平台,提高了患者预约量和质量,并降低了目标市场的获客成本 [23][24] 公司战略和发展方向及行业竞争 - 公司确立了三大战略支柱:1)提高股东价值和实现盈利;2)扩大产品组合和分销;3)通过M&A拓展业务 [17][47][49] - 公司大幅削减运营成本,预计2024年运营费用将较2023年减少55.4%,以投资于增长动力,如Lap-Band 2.0 FLEX的推广 [20][22][47] - 公司认为Lap-Band手术是一种安全、可调节和可逆的手术方式,在GLP-1药物使用受限的情况下,将成为一个有增长潜力的市场机会 [15][16][31][32] - 公司正积极寻求战略性和协同性的并购机会,以拓展产品组合,提高竞争力 [9][49] 管理层对经营环境和未来前景的评论 - 管理层认为,随着GLP-1受体激动剂在减肥治疗中的普及,消除了对肥胖和医疗干预的stigma,将带动对Lap-Band等手术的需求增加 [10][13][14][15] - 但GLP-1药物的局限性,如长期耐受性差、费用高昂等,将推动患者寻求Lap-Band等手术作为下一步的减重治疗 [14][15][16][31][32] - 管理层对Lap-Band 2.0 FLEX的市场前景持乐观态度,认为其将成为公司Lap-Band业务的增长动力 [25][26][29] - 管理层表示将继续优化营销策略,提高获客效率,并通过并购等方式拓展产品组合,以应对行业竞争 [47][49] 问答环节重要的提问和回答 无提问和回答内容

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) | | | For the fiscal year ended December 31, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other jurisdiction of incorporation or organization) (IRS Employer Identificatio ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President & Chief Executive Officer Caroline Apovian - Member-ReShape Scientific Advisory Tom Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group. Operator Good afternoon and thanks for joining the ReShape Lifesciences Third Quarter 2023 Conference Call. I would now like to turn the call over to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or o ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Michael Miller - Rx Communications, IR Paul Hickey - President and CEO Tom Stankovich - CFO Christine Ren-Fielding - Member, ReShape Scientific Advisory Board Conference Call Participants Anthony Vendetti - Maxim Operator Good afternoon, and thank you for joining the ReShape Lifesciences Second Quarter 2023 Conference Call. I would like to turn the call over to Michael Miller from Rx Comm ...